First EU-licensed poultry vaccine to prevent development of ILT, IBD and MD without the risk of reversion to virulence of ILT
Rahway, N.J., June 12, 2023 – Merck Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), announced today that the European Commission has approved INNOVAX®-ILT-IBD, a dual-construct HVT vaccine that provides long-term protection against infectious laryngotracheitis (ILT), infectious bursal disease (IBD) and Marek’s disease (MD). Following the centralized approval procedure, all European Union countries in which INNOVAX-ILT-IBD is licensed will update their national registrations.
INNOVAX-ILT-IBD is the first and only vaccine approved in the EU to provide combined protection against the development of ILT, IBD and MD in a single injection. The approval follows a positive opinion from the Committee for Veterinary Medicinal Products (CVMP) received in April 2023.
“For decades, Merck Animal Health has discovered and developed innovative, science-driven ways to preserve poultry well-being while maximizing our customers’ potential to contribute to global food production and safety,” said Fernando Vargas, Global Poultry Technical Director at Merck Animal Health. “Currently, there are no products available in the EU that prevent both, infectious laryngotracheitis, or ILT, and infectious bursal disease, without the risk of reversion to virulence. These are two of the most threatening diseases to poultry operations, making prevention by vaccination and biosecurity measures essential. With INNOVAX-ILT-IBD, poultry producers can have peace of mind that their birds have protection against three viruses in one.”
Building on Merck Animal Health’s legacy of protection offered by INNOVAX-ILT, INNOVAX-ILT-IBD features two ILT glycoprotein inserts instead of one. Furthermore, clinical trial data show that INNOVAX-ILT-IBD has an early onset and a long duration of immunity.1
“Infectious laryngotracheitis and infectious bursal disease are highly contagious respiratory diseases that can quickly infect entire poultry farms, causing stress and other debilitating symptoms that can have a long-term effect on health and productivity,” said Fernando Vargas, Global Poultry Technical Director at Merck Animal Health. “While we’ve seen tremendous preventive advancements in the field with monovalent vector vaccines, recent studies show that monovalent HVT vaccines can interfere with one another when combined – causing gaps in protection. We are thrilled to introduce INNOVAX-ILT-IBD, which combines the proven efficacy of our individual ILT and IBD vaccines into one vaccine, providing life-long protection for chickens while saving time and labor in the field.”
INNOVAX-ILT-IBD can be administered in the hatchery to layers and breeder flocks to increase early-life protection, and to broilers, both by subcutaneous injection (at day-old) or in ovo application (around 18 days of incubation). The product can be used in combination with other Merck Animal Health poultry products, including NOBILIS® RISMAVAC, NOBILIS® ND Clone 30, NOBILIS® ND C2, NOBILIS® IB Ma5 or NOBILIS® IB 4-91.
Detailed conditions for the use of INNOVAX-ILT-IBD in chickens described in its Summary of Product Characteristics (SPC) will be translated in all EU languages for publishing by individual regulatory authorities.
About Merck Animal Health
At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than a century, we’ve been at the forefront of research, bringing forward medicines, vaccines and innovative health solutions for the world’s most challenging diseases. Merck Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA, is the global animal health business of Merck. Through its commitment to The Science of Healthier Animals®, Merck Animal Health offers veterinarians, farmers, pet owners and governments one of the widest ranges of veterinary pharmaceuticals, vaccines and health management solutions and services as well as an extensive suite of connected technology that includes identification, traceability and monitoring products. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals and the people who care for them. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.merck-animal-health.com and connect with us on LinkedIn, Facebook, Twitter and Instagram.
Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA
This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2022 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).
- INNOVAX-ILT-IBD Prescribing Information, Rahway, NJ: Merck Animal Health.